Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease.
about
Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectivesc-Jun N-terminal Kinase (JNK) Signaling as a Therapeutic Target for Alzheimer's DiseaseNeuronal endoplasmic reticulum stress in axon injury and neurodegenerationThe role of the LRRK2 gene in ParkinsonismTime to change the blind men and the elephant approach to Parkinson disease?Effects of parkinsonism on health status in welding exposed workersPrecompetitive Data Sharing as a Catalyst to Address Unmet Needs in Parkinson's DiseaseTherapeutic directions for Parkinson's diseaseSerum urate as a predictor of clinical and radiographic progression in Parkinson disease.JNK3 mediates paraquat- and rotenone-induced dopaminergic neuron death.Longitudinal follow-up of SWEDD subjects in the PRECEPT StudyThe diagnostic accuracy of dopamine transporter SPECT imaging to detect nigrostriatal cell loss in patients with Parkinson's disease or clinically uncertain parkinsonism: a systematic review.Monitoring of 30 marker candidates in early Parkinson disease as progression markers.Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease.Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.Targeting protein kinases in central nervous system disordersPotential future neuroprotective therapies for neurodegenerative disorders and stroke.A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY-PD III).Parkinson's disease-implicated kinases in the brain; insights into disease pathogenesis.Serum cholesterol and the progression of Parkinson's disease: results from DATATOP.Urate as a predictor of the rate of clinical decline in Parkinson disease.Clinical progression in Parkinson disease and the neurobiology of axons.Defining at-risk populations for Parkinson's disease: lessons from ongoing studies.FMR1 gene expansion and scans without evidence of dopaminergic deficits in parkinsonism patients.Adjunctive and long-acting nanoformulated antiretroviral therapies for HIV-associated neurocognitive disordersSeniors with Parkinson's disease: initial medical treatment.Imaging prodromal Parkinson disease: the Parkinson Associated Risk Syndrome Study.Mendelian randomization of serum urate and parkinson disease progression.Unbiased approaches to biomarker discovery in neurodegenerative diseasesInosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.The new small-molecule mixed-lineage kinase 3 inhibitor URMC-099 is neuroprotective and anti-inflammatory in models of human immunodeficiency virus-associated neurocognitive disorders.Intracellular signalling pathways in dopamine cell death and axonal degeneration.Pathophysiological roles for purines: adenosine, caffeine and urate.Medical management of Parkinson's disease: focus on neuroprotectionSerum urate and probability of dopaminergic deficit in early "Parkinson's disease".The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson's disease.Prevention of the degeneration of human dopaminergic neurons in an astrocyte co-culture system allowing endogenous drug metabolismProgressive dopaminergic cell loss with unilateral-to-bilateral progression in a genetic model of Parkinson diseaseIncreased risk of parkinsonism associated with welding exposure.A scan without evidence is not evidence of absence: Scans without evidence of dopaminergic deficit in a symptomatic leucine-rich repeat kinase 2 mutation carrier.
P2860
Q26747508-93612275-D088-4002-811F-DC107BD0D797Q26770431-C969078B-3D25-4393-9C45-7091C663A911Q26826912-084167A3-571D-465C-A807-11815E2C4EE1Q27023749-81C330D3-2128-432F-B3CE-58428780C279Q27693350-C23C5AF2-FA04-4450-B37E-73C97814022AQ28392994-3350CB9B-219C-4DE2-96A1-A53BD60E136EQ28601965-07EFA026-868D-4625-9CB6-7CB6F2790290Q28743874-A73F6504-2267-4810-B8CC-B5A59D30114FQ30440692-0014BB0A-FAAD-4674-89B6-63A8E8B96AB1Q30498929-D39A9D0F-BE88-48CE-B3ED-6C080A73A54FQ30578973-A353B568-BA1F-445A-967D-7C7BFD462D8FQ30635471-8A2B8578-DBB3-469B-AE05-C21D389A1B97Q30783504-1D8244D2-07E2-4738-836A-9141F7AEF102Q33602588-328F31DF-4392-4546-BCF1-4AB32DA9DAB9Q33654498-ED43D2B7-E0F6-470E-8AF1-1793EA715FA8Q33671660-29718086-D4FD-4558-A7D1-102162BB5D97Q33687436-22E120B7-0CE8-47A2-9D06-F39683608D72Q33753874-2F95A224-33A3-435F-9557-D19838DE7B54Q33797449-DBAC32C2-9E70-442D-AF3E-88BEA92C1847Q33996828-1BB30D9F-C52E-47B9-9304-A0A491756AB0Q34019732-E3778839-B291-42D8-8C39-9D907F00A9F6Q34052764-F432E392-968C-402D-ABF3-847E5F6DAEFCQ34234632-EEBD1835-78EB-4071-93B4-89F1527AF566Q34238643-0D4FA97D-1BA5-45B6-87F0-3B05116E42E2Q34507098-0F1889C6-C298-4ECC-B74E-59073C0B34B4Q34508143-075B1D13-F502-48E2-833D-A7804A06342BQ34553777-24AD73D1-0B74-4BB9-B2F7-D477B3B7941AQ34576895-7C2629B2-4A4D-4A77-9A08-534519C426F4Q34625918-F7CF67E8-077C-4E88-A228-88097134BDB5Q34658560-1312F997-17EC-4064-8886-FF1F53AB1C84Q34769218-6809B508-DB5F-4367-82A0-0CBB5E91776EQ34936423-F3F105E4-3373-4DBD-B748-BEEB1FE0A5EAQ35008049-ABF4C8DC-9426-4D24-A09D-3C9C5E20C125Q35092165-4B960C13-0BCF-4C48-9B10-3A5FEFA34256Q35148529-45750AB1-EA45-4A93-9302-55AFDCAF1EF4Q35894167-95318CCA-C5A9-4789-AEA3-2E5217D7C7CCQ35978121-098ED44A-259A-474A-8D96-90179C34EB7EQ36300804-1830793A-20BF-47F1-94B3-5C163E3B28BCQ36837642-D7BDD7D1-9883-4073-A28C-D58896ABBD5EQ36972794-1285C887-455F-4656-9800-EE0F2BA99B08
P2860
Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Mixed lineage kinase inhibitor ...... ty in early Parkinson disease.
@en
Mixed lineage kinase inhibitor ...... ty in early Parkinson disease.
@nl
type
label
Mixed lineage kinase inhibitor ...... ty in early Parkinson disease.
@en
Mixed lineage kinase inhibitor ...... ty in early Parkinson disease.
@nl
prefLabel
Mixed lineage kinase inhibitor ...... ty in early Parkinson disease.
@en
Mixed lineage kinase inhibitor ...... ty in early Parkinson disease.
@nl
P1433
P1476
Mixed lineage kinase inhibitor ...... ty in early Parkinson disease.
@en
P2093
Parkinson Study Group PRECEPT Investigators
P304
P356
10.1212/01.WNL.0000277648.63931.C0
P407
P577
2007-09-19T00:00:00Z